Biomea Fusion (BMEA) Stock Forecast, Price Target & Predictions


BMEA Stock Forecast


Biomea Fusion (BMEA) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $23.33, with a high of $40.00 and a low of $11.00. This represents a 553.50% increase from the last price of $3.57.

- $8 $16 $24 $32 $40 High: $40 Avg: $23.33 Low: $11 Last Closed Price: $3.57

BMEA Stock Rating


Biomea Fusion stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (87.50%), 1 Hold (12.50%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 1 7 Strong Sell Sell Hold Buy Strong Buy

BMEA Price Target Upside V Benchmarks


TypeNameUpside
StockBiomea Fusion553.50%
SectorHealthcare Stocks 25.10%
IndustryBiotech Stocks 61.24%

Price Target Trends


1M3M12M
# Anlaysts--7
Avg Price Target--$17.29
Last Closing Price$3.57$3.57$3.57
Upside/Downside--384.31%
Ratings Trends

DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 25342--9
Jan, 25342--9
Dec, 24342--9
Nov, 24353--11
Oct, 24353--11
Analyst Price Target Forecasts

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 31, 2024Joseph CatanzaroPiper Sandler$19.00$10.3483.75%432.21%
Oct 30, 2024Peter LawsonBarclays$11.00$12.06-8.79%208.12%
Oct 22, 2024Joseph PantginisH.C. Wainwright$40.00$11.24255.87%1020.45%
Sep 27, 2024Joseph CatanzaroPiper Sandler$10.00$9.901.01%180.11%
Jun 07, 2024Joseph PantginisH.C. Wainwright$15.00$4.24253.77%320.17%
Jun 07, 2024George FarmerScotiabank$21.00$11.2786.34%488.24%
Jun 07, 2024Peter LawsonBarclays$5.00$11.27-55.63%40.06%
Jun 14, 2022Joseph PantginisH.C. Wainwright$16.00$8.5088.24%348.18%
Analyst Rating Forecasts

DateCompanyPrevious RatingNew RatingRating Change
Oct 31, 2024Piper SandlerOverweightOverweighthold
Oct 30, 2024BarclaysEqual-WeightEqual-Weighthold
Oct 22, 2024H.C. WainwrightBuyBuyhold
Oct 09, 2024EF HuttonBuyinitialise
Sep 27, 2024ScotiabankOutperformOutperformhold
Sep 27, 2024Piper SandlerOverweightOverweighthold
Sep 27, 2024ScotiabankSector OutperformSector Outperformhold
Sep 27, 2024H.C. WainwrightBuyBuyhold
Sep 27, 2024BarclaysEqual-WeightEqual-Weighthold
Sep 26, 2024Rodman & RenshawNeutralBuyupgrade

Financial Forecast


EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.44-----
Avg Forecast$-3.32$-3.89$-3.55$-3.30$-3.38$-2.13
High Forecast$-3.14$-3.44$-2.82$-0.84$-0.88$-2.13
Low Forecast$-3.50$-4.18$-4.30$-5.24$-4.97$-2.13
Surprise %3.61%-----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast-$10.00M$1.88M$4.33M$29.19M$198.99M
High Forecast-$10.00M$1.88M$4.33M$29.19M$198.99M
Low Forecast-$10.00M$1.88M$4.33M$29.19M$198.99M
Surprise %------

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-117.25M-----
Avg Forecast$-107.69M$-130.06M$-121.44M$-161.05M$-163.59M$-72.79M
High Forecast$-107.02M$-117.41M$-96.21M$-28.75M$-30.15M$-72.79M
Low Forecast$-119.37M$-142.71M$-146.68M$-178.61M$-169.36M$-72.79M
Surprise %8.89%-----

BMEA Forecast FAQ


Is Biomea Fusion stock a buy?

Biomea Fusion stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Biomea Fusion is a favorable investment for most analysts.

What is Biomea Fusion's price target?

Biomea Fusion's price target, set by 8 Wall Street analysts, averages $23.33 over the next 12 months. The price target range spans from $11 at the low end to $40 at the high end, suggesting a potential 553.50% change from the previous closing price of $3.57.

How does Biomea Fusion stock forecast compare to its benchmarks?

Biomea Fusion's stock forecast shows a 553.50% upside, outperforming the average forecast for the healthcare stocks sector (25.10%) and outperforming the biotech stocks industry (61.24%).

What is the breakdown of analyst ratings for Biomea Fusion over the past three months?

  • February 2025: 33.33% Strong Buy, 44.44% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.
  • January 2025: 33.33% Strong Buy, 44.44% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 33.33% Strong Buy, 44.44% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.

What is Biomea Fusion’s EPS forecast?

Biomea Fusion's average annual EPS forecast for its fiscal year ending in December 2024 is $-3.89, marking a 13.08% increase from the reported $-3.44 in 2023. Estimates for the following years are $-3.55 in 2025, $-3.3 in 2026, $-3.38 in 2027, and $-2.13 in 2028.

What is Biomea Fusion’s revenue forecast?

Biomea Fusion's average annual revenue forecast for its fiscal year ending in December 2024 is $10M, reflecting a 0% decrease from the reported $0 in 2023. The forecast for 2025 is $1.88M, followed by $4.33M for 2026, $29.19M for 2027, and $198.99M for 2028.

What is Biomea Fusion’s net income forecast?

Biomea Fusion's net income forecast for the fiscal year ending in December 2024 stands at $-130M, representing an 10.92% increase from the reported $-117M in 2023. Projections indicate $-121M in 2025, $-161M in 2026, $-164M in 2027, and $-72.794M in 2028.